Cannabis Use Disorder – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036
- Published Date : June 13, 2026
- Updated On : September 4, 2026
- Pages : 154
Cannabis Use Disorder Market Outlook and Forecast
Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cannabis Use Disorder Overview
Cannabis use disorder (CUD) is a neuropsychiatric disorder characterized by persistent problematic cannabis use, impaired control, withdrawal symptoms, and functional or psychosocial impairment. Repeated cannabis exposure can produce adaptive changes in endocannabinoid and reward circuitry that may contribute to craving and continued use. There is currently no FDA-approved medication specifically for CUD, leaving behavioral approaches such as cognitive-behavioral therapy, motivational enhancement therapy, and contingency management as the principal evidence-based treatments. Pharmacologic development remains early, with investigations spanning cannabinoid signaling, FAAH and MAGL inhibition, glutamatergic modulation, orexin pathways, and other mechanisms, but recent evidence continues to show modest and heterogeneous efficacy. AEF0117, a signaling-specific CB1 inhibitor, demonstrated encouraging effects in earlier-phase studies, but its Phase 2b trial did not meet the primary endpoint in the overall population, underscoring the difficulty of translating endocannabinoid biology into durable clinical benefit. FAAH inhibitors and other endocannabinoid approaches remain investigational, while newer clinical studies continue to evaluate cannabinoid-based and behavioral combinations. For stakeholders, CUD represents a substantial unmet need and an emerging pharmacotherapy opportunity, with the key challenge being the development of safe treatments that meaningfully reduce cannabis use and support sustained recovery.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
Cannabis Use Disorder Market Outlook and Forecast
Thelansis’s “Cannabis Use Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cannabis Use Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Cannabis Use Disorder Overview
Cannabis use disorder (CUD) is a neuropsychiatric disorder characterized by persistent problematic cannabis use, impaired control, withdrawal symptoms, and functional or psychosocial impairment. Repeated cannabis exposure can produce adaptive changes in endocannabinoid and reward circuitry that may contribute to craving and continued use. There is currently no FDA-approved medication specifically for CUD, leaving behavioral approaches such as cognitive-behavioral therapy, motivational enhancement therapy, and contingency management as the principal evidence-based treatments. Pharmacologic development remains early, with investigations spanning cannabinoid signaling, FAAH and MAGL inhibition, glutamatergic modulation, orexin pathways, and other mechanisms, but recent evidence continues to show modest and heterogeneous efficacy. AEF0117, a signaling-specific CB1 inhibitor, demonstrated encouraging effects in earlier-phase studies, but its Phase 2b trial did not meet the primary endpoint in the overall population, underscoring the difficulty of translating endocannabinoid biology into durable clinical benefit. FAAH inhibitors and other endocannabinoid approaches remain investigational, while newer clinical studies continue to evaluate cannabinoid-based and behavioral combinations. For stakeholders, CUD represents a substantial unmet need and an emerging pharmacotherapy opportunity, with the key challenge being the development of safe treatments that meaningfully reduce cannabis use and support sustained recovery.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal articles, third-party research databases)
Deliverables format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market forecast (2026–2036)
- Bottom-up patient-based market forecasts validated through the top-down sales methodology
- Covers clinically and commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and patient share projections
- Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and patient share?
- Which events will have the greatest impact on the market’s trajectory?
- What insights do interviewed experts provide on current and emerging treatments?
- Which pipeline products show the most promise, and what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for target profiles?
- What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
- and more…
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..
2. Disease Context
- Disease definition, classification, etiology and pathophysiology, drug targets,etc.
3. Epidemiology
- Key takeaways
- Incidence / Prevalence
- Diagnosed and Drug-Treated populations
- Comorbidities
- Other relevant patient segments
4. Market Size and Forecast
- Key takeaways
- Market drivers and constraints
- Drug-class specific trends
- Country-specific trends
5. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
- Notable early-phase pipeline
6. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)